Explainer
How to read a prescription drug label and boxed warnings
In the US, the prescription drug label is FDA's main way of telling clinicians and patients how to use a medicine; the company proposes it, FDA reviews it, and a drug whose label is unacceptable is not approved.[1][2] The professional label opens with a short summary called Highlights, followed by the Full Prescribing Information in numbered sections.[3] A boxed warning, placed at the top in a black box, flags serious risks that may lead to death or serious injury.[4][5]
This page explains how US drug labels are organised. It is general information, not medical advice, and it gives no dosing guidance. Ask your prescriber or pharmacist about your own medicines, and don’t stop or change a prescribed drug without talking to them.
FDA calls prescription drug labeling its primary tool for communicating drug information to health professionals, patients and caregivers.[1] Every prescription medicine has Prescribing Information, written for professionals, plus carton and container labeling, and many also have labeling written for patients.[1] The drug company proposes the text and FDA reviews it. If FDA finds the labeling for a new medicine unacceptable, the medicine is not approved.[2] Companies must update the label when new information makes it inaccurate, false or misleading.[6]
The layout: Highlights, then the full label
The most common format, the Physician Labeling Rule format, has three parts: Highlights of Prescribing Information, a Table of Contents and the Full Prescribing Information.[3] By regulation, Highlights must state that they do not include all the information needed to use the drug safely and effectively.[3] Highlights also show:
- Initial U.S. Approval, the year the active ingredient was first approved. For Lipitor (atorvastatin) it is 1996.[7]
- Recent Major Changes to the boxed warning, indications, dosage, contraindications or warnings sections.[7]
- Revision date, the month and year of the latest revision.[7]
The sections that matter most to patients
| Section | What it holds |
|---|---|
| Boxed warning | Certain contraindications or serious warnings, especially those that may lead to death or serious injury, that FDA may require to be shown in a box[4] |
| 1 Indications and usage | FDA-approved uses backed by substantial evidence of effectiveness, with benefits outweighing risks[8] |
| 4 Contraindications | Situations where the drug should not be used because the risk clearly outweighs any benefit[9] |
| 5 Warnings and precautions | Risks that affect the decision to prescribe, monitoring needed for safe use, and ways to prevent harm[10] |
| 6 Adverse reactions | Undesirable effects reasonably associated with the drug, not every event seen during use[11] |
| 8 Use in specific populations | Pregnancy, lactation, reproductive potential, children, older adults and people with conditions such as kidney or liver impairment[12] |
| 14 Clinical studies | The studies supporting effectiveness: design, population, endpoints and results[13] |
| 17 Patient counseling information | What patients need to know to use the drug safely and effectively[14] |
Boxed warnings. The box sits at the very top of the Full Prescribing Information, in bold text surrounded by a black line, and FDA notes it is sometimes called a “black-box warning”.[5] It ordinarily must be based on clinical data, but serious toxicity seen in animals can also justify one when clinical data are absent.[4] For reading risk figures in the Adverse Reactions and Clinical Studies sections, see relative vs absolute risk.[11][15]
“Adverse reaction” versus “adverse event”. In labeling, an adverse reaction is an undesirable effect reasonably associated with use of the drug. The definition does not include every adverse event observed during use of the drug.[11] The Clinical Studies section ordinarily describes the studies that support effectiveness for the labeled uses, including their design, population, endpoints and results.[13]
Pregnancy and breastfeeding
FDA’s Pregnancy and Lactation Labeling Rule took effect on 30 June 2015. It removed the old pregnancy letter categories (A, B, C, D and X) from prescription labels and added a subsection on females and males of reproductive potential. Over-the-counter medicines were not affected.[16] Section 8 now covers pregnancy, lactation and reproductive potential, alongside children, older adults and people with conditions such as kidney or liver impairment.[12]
Labels written for patients
FDA requires a Medication Guide for certain drugs, for example when patient information could help prevent serious adverse reactions, and it must be handed to patients.[17] Other printed leaflets may not be FDA-approved: consumer medication information, developed by someone other than the drug company, is not reviewed by FDA or by the drug company. FDA-approved patient labeling includes Medication Guides, Patient Package Inserts and Instructions for Use. In May 2023 FDA proposed a new FDA-approved format called Patient Medication Information.[18]
Where to find a label
The National Library of Medicine’s DailyMed database held 158,967 labels submitted to FDA by companies when checked on 7 November 2026. It is not a complete listing of every FDA-regulated product.[19] Generic drugs carry the same label as the brand, with certain exceptions. See generic drugs and biosimilars.[20] Recalls and safety alerts follow a separate process, covered in the FDA recall process page.[21]
Read next
Cholesterol-lowering drugs: statins, PCSK9, Lipfendra and more
A sourced guide to statins, ezetimibe, bempedoic acid, PCSK9 drugs, inclisiran, oral enlicitide (Lipfendra) and obicetrapib: how they work and the evidence.
Questions readers ask
What is a boxed warning?
Under FDA rules, certain contraindications or serious warnings, especially those that may lead to death or serious injury, can be required to appear in a box with a heading that includes the word WARNING. It sits at the start of the Full Prescribing Information and is sometimes called a black-box warning.[4][5]
What is the difference between a contraindication and a warning?
A contraindication describes situations where the drug should not be used because the risk clearly outweighs any possible benefit. Warnings and precautions cover risks that affect the decision to prescribe, monitoring needed for safe use, and ways to prevent or reduce harm.[9][10]
What happened to pregnancy categories A, B, C, D and X?
FDA's Pregnancy and Lactation Labeling Rule, effective 30 June 2015, removed the letter categories from prescription drug labels and added a subsection on females and males of reproductive potential. OTC drugs were not affected.[16]
What is a Medication Guide?
It is FDA-approved patient labeling required for certain drugs, for example when patient information could help prevent serious adverse reactions. It must be given to patients.[17]
Is the leaflet from my pharmacy approved by FDA?
Not necessarily. Consumer medication information developed by someone other than the drug company is not reviewed or approved by FDA or by the drug company. FDA-approved patient labeling includes Medication Guides, Patient Package Inserts and Instructions for Use.[18][17]
Where can I read the full label for a drug?
The National Library of Medicine's DailyMed database held 158,967 labels submitted to FDA by companies when checked on 7 November 2026, though it is not a complete listing.[19]
Sources
· 21 claims from 4 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
FDA calls prescription drug labeling its primary tool for communicating drug information to health professionals, patients and caregivers; it includes the Prescribing Information, carton and container labeling, and for many drugs patient labeling. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · introduction (retrieved 2026-11-07)
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · introduction (retrieved 2026-11-07)
- [2]
The drug company proposes the labeling and FDA reviews it; if FDA finds the labeling for a new medicine unacceptable, the medicine is not approved. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · introduction (retrieved 2026-11-07)
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · introduction (retrieved 2026-11-07)
- [3]
The most common Prescribing Information format, the Physician Labeling Rule format, has three parts - Highlights, a Table of Contents and the Full Prescribing Information - and Highlights must say they do not include all the information needed to use the drug safely. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · What Is Prescribing Information? (retrieved 2026-11-07)
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(a)(1) (retrieved 2026-11-07)
- [4]
Under 21 CFR 201.57, FDA may require certain contraindications or serious warnings, especially those that may lead to death or serious injury, to be placed in a box with a heading that includes the word WARNING; a boxed warning ordinarily must be based on clinical data but can rest on serious animal toxicity when clinical data are absent. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(1) (retrieved 2026-11-07)
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(1) (retrieved 2026-11-07)
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(1) (retrieved 2026-11-07)
- [5]
FDA says the boxed warning, sometimes called a black-box warning, sits prominently at the start of the Full Prescribing Information inside a single black line. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Table C, Boxed Warning (retrieved 2026-11-07)
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Table C, Boxed Warning (retrieved 2026-11-07)
- [6]
Drug companies must update their Prescribing Information when new information makes it inaccurate, false or misleading. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · When Is Prescribing Information Updated? (retrieved 2026-11-07)
- [7]
Highlights show the Initial US Approval year (for example 1996 for atorvastatin, sold as Lipitor), recent major changes to key safety and use sections, and the revision date of the label. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Key Features of Highlights (retrieved 2026-11-07)
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Key Features of Highlights (retrieved 2026-11-07)
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Key Features of Highlights (retrieved 2026-11-07)
- [8]
The Indications and Usage section lists FDA-approved uses supported by substantial evidence of effectiveness, with benefits that outweigh risks. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Table C, section 1 (retrieved 2026-11-07)
- [9]
The Contraindications section must describe situations in which the drug should not be used because the risk clearly outweighs any possible benefit. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(5) (retrieved 2026-11-07)
- [10]
The Warnings and Precautions summary covers information that would affect the decision to prescribe, monitoring critical to safe use, and steps to prevent or reduce harm. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(a)(10) (retrieved 2026-11-07)
- [11]
For labeling, an adverse reaction is an undesirable effect reasonably associated with the drug; it does not include every adverse event seen during use. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(7) (retrieved 2026-11-07)
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(7) (retrieved 2026-11-07)
- [12]
Section 8, Use in Specific Populations, covers pregnancy, lactation, reproductive potential, children, older adults and patients with conditions such as kidney or liver impairment. confirmedas of 2026-11-07
- Frequently Asked Questions about Labeling for Prescription Medicines · US Food and Drug Administration · Primary source · Table C, section 8 (retrieved 2026-11-07)
- [13]
The Clinical Studies section ordinarily describes the studies supporting effectiveness, including design, population, endpoints and results. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(15) (retrieved 2026-11-07)
- [14]
Section 17, Patient Counseling Information, must contain what patients need to use the drug safely and effectively. confirmedas of 2026-11-07
- 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products · Electronic Code of Federal Regulations · Primary source · 21 CFR 201.57(c)(18) (retrieved 2026-11-07)
- [15]
The risk difference between two groups is often called the absolute risk reduction (or absolute risk increase) and can be shown as a percentage, a decimal or a count such as 10 out of 1000. confirmedas of 2026-11-07
- Cochrane Handbook, Chapter 15: Interpreting results and drawing conclusions · Cochrane · Primary source · Section 15.4.1 (retrieved 2026-11-07)
- Cochrane Handbook, Chapter 15: Interpreting results and drawing conclusions · Cochrane · Primary source · Section 15.4.1 (retrieved 2026-11-07)
- [16]
FDA's Pregnancy and Lactation Labeling Rule, effective 30 June 2015, removed the pregnancy letter categories A, B, C, D and X and added a section on females and males of reproductive potential; OTC drugs are not affected. confirmedas of 2026-11-07
- Pregnancy and Lactation Labeling (Drugs) Final Rule · US Food and Drug Administration · Primary source · PLLR summary (retrieved 2026-11-07)
- Pregnancy and Lactation Labeling (Drugs) Final Rule · US Food and Drug Administration · Primary source · PLLR summary (retrieved 2026-11-07)
- Pregnancy and Lactation Labeling (Drugs) Final Rule · US Food and Drug Administration · Primary source · PLLR summary (retrieved 2026-11-07)
- Pregnancy and Lactation Labeling (Drugs) Final Rule · US Food and Drug Administration · Primary source · PLLR summary (retrieved 2026-11-07)
- [17]
A Medication Guide is FDA-approved patient labeling required for certain drugs, for example when patient information could help prevent serious adverse reactions; it must be given to patients. confirmedas of 2026-11-07
- Medication Guides · US Food and Drug Administration · Primary source · What are Medication Guides? (retrieved 2026-11-07)
- Medication Guides · US Food and Drug Administration · Primary source · What are Medication Guides? (retrieved 2026-11-07)
- Medication Guides · US Food and Drug Administration · Primary source · What are Medication Guides? (retrieved 2026-11-07)
- [18]
FDA-approved patient labeling includes Medication Guides, Patient Package Inserts and Instructions for Use; consumer medication information is developed by someone other than the drug company, and neither FDA nor the drug company reviews it; in May 2023 FDA proposed a new FDA-approved Patient Medication Information format. confirmedas of 2026-11-07
- Medication Guides · US Food and Drug Administration · Primary source · What types of patient labeling are available? (retrieved 2026-11-07)
- Medication Guides · US Food and Drug Administration · Primary source · What types of patient labeling are available? (retrieved 2026-11-07)
- Medication Guides · US Food and Drug Administration · Primary source · What types of patient labeling are available? (retrieved 2026-11-07)
- Medication Guides · US Food and Drug Administration · Primary source · What types of patient labeling are available? (retrieved 2026-11-07)
- [19]
The National Library of Medicine's DailyMed database held 158,967 labels submitted to FDA by companies when checked on 7 November 2026, though it is not a complete listing. confirmedas of 2026-11-07
- About DailyMed · National Library of Medicine · Primary source · home page counter (retrieved 2026-11-07)
- About DailyMed · National Library of Medicine · Primary source · home page (retrieved 2026-11-07)
- [20]
A generic's label is the same as the brand-name label, with certain exceptions. confirmedas of 2026-11-07
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic drugs must meet the same high standards (retrieved 2026-11-07)
- [21]
FDA describes a recall as a firm's action to remove a product from the market, conducted on the firm's own initiative, at FDA's request, or by FDA order under statutory authority. confirmedas of 2026-10-11
- Recalls Background and Definitions · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Nov 7, 2027.
Cite this page
"How to read a prescription drug label and boxed warnings." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/how-drug-labels-work
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.